Ex parte CHANG - Page 5




              Appeal No. 1995-3148                                                                                     
              Application No. 08/011,130                                                                               


              which would have led a person having ordinary skill to the claimed method.  Pro-Mold &                   
              Tool Co. v. Great Lakes Plastics, Inc., 75 F.3d 1568, 1573, 37 USPQ2d 1626, 1629 (Fed.                   
              Cir. 1996).  In our judgment, the only reason or suggestion to modify the references to                  
              arrive at the present invention comes from appellant’s specification.  Accordingly, the                  
              rejection of claims 6 and 8 through 14 under 35 U.S.C. § 103 is reversed.                                
                                             35 U.S.C. §§ 101 and 112                                                  
                     U.S. Patent No. 5,872,222 (the ‘222 patent) issued from application serial no.                    
              07/993,291, an application closely related to the present application.  Claims 1 and 7 of                
              the ‘222 patent read as follows:                                                                         
                     1.  A conjugate comprising a substantially nonimmunogenic polymer coupled                         
                     with a plurality of binding molecules, each being specific for an antigen on a                    
                     T cell, and said binding molecules lacking an Fc portion.                                         
                     7.  An improved method for producing antibodies against an immunogen,                             
                     comprising administering the conjugate of claim 1 to a host animal together                       
                     with the immunogen and thereby increasing the immunogenic response                                
                     against the antigen, and screening for antibodies, or cells producing                             
                     antibodies, which are specifically reactive with the immunogen.                                   
                     The patented conjugate (claim 1 of ‘222) is closely related to and parallels the                  
              pharmaceutical conjugates that are the subject of this appeal, inasmuch as the                           
              patented conjugate is administered to a host animal together with an immunogen to                        
              increase the host’s response to the immunogen (claim 7 of ‘222).                                         




                                                          5                                                            





Page:  Previous  1  2  3  4  5  6  7  8  Next 

Last modified: November 3, 2007